Thursday, 5 November 2026European Markets

ORPEA Stock Plunges 30% In Recent Sell-Off

Loading stream...

(vianews) - orpea (orp.pa) shares had experienced an astounding 30.07% drop over 10 sessions, declining from eur0.01 to eur0.00 at 15:24 est on tuesday - nearly following suit with cac 40 index which dropped 0.24% to eur7,787.04 also trending down since friday session close. orpea's close of eur0.00 represented 98.53% lower than its 52-week high of eur0.88!

about orpea

orpea sa is a healthcare provider specializing in nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, psychiatric hospitals and home care services with operations across 22 countries worldwide. offering personalized support services such as accommodation, meals and laundry as well as daily event and workshop services at its post-acute and rehabilitation hospitals for a range of conditions while its psychiatric hospitals specialize in treatment of various mental health disorders; additionally offering home care services like housekeeping assistance daily life assistance movement assistance services since 1989 from its headquarters based in puteaux france since 1989!

yearly analysis

orpea (epa:orp) with an indicative share price of eur0.01, orpea is currently trading at an impressively discounted level compared to its 52-week low of eur0.01 from last year at this time. furthermore, its share price has experienced significant drop of 47.6% since reaching eur0.02 at this same point last year. analysts remain hopeful about orpea's growth prospects despite its obstacles; they anticipate sales will rise 6.3% this year and 6.2% next. this increase should be driven by orpea's focus on expanding home healthcare services while simultaneously increasing operational efficiencies. though orpea's financial performance has been poor over recent years, its fundamentals remain strong. orpea holds an exceptional market position within european home healthcare with significant market shares across many countries; furthermore, orpea boasts a diverse revenue stream from operations in multiple european nations offering various services. investors with confidence in the european home healthcare industry and orpea's ability to turn around its financial performance should carefully consider investing in this company, but should do their own due diligence first before making any investment decisions.

technical analysis

orpea's stock performance: exploration of moving averages and volume orpea's stock price has experienced a precipitous decrease, falling well below both its 50-day and 200-day moving averages. the 50-day average currently sits at eur0.01, far less than eur0.10 at its 200-day average; investors have expressed concern regarding this divergence from historical performance trends. orpea trading activity has seen a decrease, with today's volume reported being 59% below its average volume of 140,714,000. this drop may be attributable to investors taking a wait-and-see approach or lacking faith in orpea's near term prospects. though orpea's stock price has taken a recent hit, the company's volatility remains relatively steady. over the last week, its intraday variation average was positive at 1.06%; this dropped to negative 0.22% during last month but eventually increased positively by 4.38% by last quarter. orpea recorded its highest amplitude of average volatility at 1.58% for last week, 2.13% during month and 4.38% by quarter. conclusion - orpea's stock performance has been marked by a gradual decrease in value compared to historical trends, suggesting investors' cautious approach and declining trading activity and volatility levels for this stock. investors should closely follow orpea's financial performance and news updates in order to make informed decisions regarding their investments with this company.

quarter analysis

orpea's revenue growth has been impressive over the past year and quarter, increasing 10.7% annually and 6.3% quarterly sales growth respectively. these impressive statistics signal expansion within orpea and customer acquisition, suggesting potential profits for investors.

equity analysis

based on available information, orpea currently has an earnings per share (eps) ratio of eur-4.11. this suggests that it is currently not profitable and indicates earnings are insufficient to cover its share price, potentially creating cause for investor concern. orpea's return on equity for the last twelve months stands at -445.48% - an indicator that their investments aren't yielding returns that satisfy shareholders, which should cause concern among investors. these financial metrics suggest that orpea may not represent an attractive investment opportunity at this time, so investors should carefully review this data prior to making any definitive investment decisions.

more news about orpea (orp.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com